At a glance
ClinicalIndex Comparison RecordPhase 2Active· 33 enrolled
Drug / intervention
Larotrectinib Sulfatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
In Brief
A Phase 2 clinical trial evaluating Larotrectinib Sulfate for Central Nervous System Neoplasm and 4 related conditions. Active but no longer recruiting, targeting 33 participants across 80 sites in 2 countries.
Detailed Summary
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
CountriesCanada, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2Active
201920202021202220232024202520262027
First PostedFeb 2019
Enrollment StartOct 2019
Primary CompletionSep 2024
TodayJul 2026
Study CompletionJul 2027
First PostedFeb 8, 2019
Enrollment StartOct 25, 2019
Primary CompletionSep 30, 2024
Study CompletionJul 25, 2027
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.4 years ago
Interventions
Larotrectinib Sulfatedrug
Given PO or via NG or G tube